Levetiracetam Amarox (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. By modulating this process, the drug reduces excessive neuronal firing and stabilizes brain activity, thereby decreasing the likelihood of seizure occurrence.

The dosage of Levetiracetam Amarox is individualized by the prescribing clinician. Factors such as seizure type, patient age, weight, renal function, and overall treatment plan determine the appropriate dose, which should be followed as directed by a qualified healthcare professional.

Safety data for levetiracetam during pregnancy and lactation are limited. Prescribers must weigh the potential benefits against possible risks to the fetus or infant. If breastfeeding, the infant may be exposed to the drug, and a healthcare provider should be consulted to assess suitability.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levetiracetam has a distinct mechanism involving SV2A binding, which results in fewer enzyme‑mediated drug interactions compared with older agents like carbamazepine or valproate. It generally offers a favorable tolerability profile, though individual response and side‑effect risk may vary among patients.

Store Levetiracetam Amarox at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Levetiracetam is taken orally, typically as tablets or an oral solution. It can be taken with or without food, according to the prescriber’s instructions, and should be swallowed whole unless a liquid formulation is prescribed.

Serious adverse events include severe allergic reactions such as Stevens‑Johnson syndrome, significant mood alterations like depression or suicidal thoughts, and rare blood disorders. Patients should be monitored closely for these signs, and any concerning symptoms should prompt immediate medical evaluation.

Individuals with a known hypersensitivity to levetiracetam or any of its excipients should avoid the medication. Patients with severe renal impairment who cannot receive appropriate dose adjustments, as well as those for whom the risk–benefit assessment is unfavorable, should not be treated with levetiracetam.